Macro Insights Weekly: Could herd immunity be a mirage?


Herd immunity ought to be the last chapter of the Covid saga. But are we anywhere near that?
Taimur Baig, Chang Wei Liang03 May 2021
  • Rapidly vaccinated societies are experiencing drops in infections, hospitalisations, and deaths
  • But vaccine hesitancy among some groups of people remains entrenched
  • Repeated emergence of virulent variants is a major concern
  • Children are not being vaccinated anywhere yet
  • Developing countries are far behind in vaccination
Photo credit: Unsplash


Commentary: Is herd immunity a mirage?

Since the pandemic began last year, the notion of herd immunity has hovered in public and policy discourse. The last chapter of the pandemic ought to be when a large part of the population is immune from developing serious disease symptoms. In the current context, herd immunity is a process where community spread is eliminated through a mix of vaccination and prior exposure to the Covid-19 infection (as both acts generate antibodies).

With vaccination rate picking up in some parts of the world, data is becoming available to establish that substantially vaccinated societies experience sharp drops in infections, hospitalisations, and deaths. Israel is a case in point, with 56% of its population fully vaccinated already. Consequently, it has already made strong progress in those three counts. The US and the UK, also making rapid progress with vaccination, have seen sizeable declines in serious illness and deaths in the past two months, an encouraging sign.





But the road to herd immunity is not nigh. Vaccine hesitancy and repeated emergence of new variants are two immediate concerns. Rumours of side effects, fears of fast-track approval process, and additional misinformation have made a minority of citizens around the world suspicious about the vaccines. Strong public campaigns and incentives are going to be needed to get the sceptical population on board, or countries will see vaccinations begin to plateau.

Cases of fully vaccinated people nonetheless becoming infected and then spreading infections are very rare, but not zero. This raises the troubling question if some of the emerging variants are reducing vaccine efficacy. So far, there is too little data available to resolve this matter, which could well turn out to be an additional, near-term complicating factor on the road to herd immunity.

Also, vaccinations are entirely targeted to the adult population so far. If children are not vaccinated, they will remain a source of infection and spread, unfortunately. It also remains to be seen if vaccine hesitancy manifests in even greater degree when it comes to parents getting their children vaccinated.

Dismayingly, the positive news about vaccine rollout is largely restricted to wealthy economies. Among the world’s most populous developing countries, including Brazil, China, India, Indonesia, and Russia, the rate of vaccination (at least one dose) is barely 15%. And now, with India, world’s largest vaccine manufacturer, imposing export restrictions due to its worsening pandemic situation, vaccine availability has become even more constrained.

Low rate of vaccination in the developing world is problematic for two reasons. First, without large swaths of the world’s population getting vaccinated, Covid-related illness and deaths will continue. Additionally, virus mutations will continue in large numbers in the inadequately vaccinated societies, posing further challenges. Secondly, many developing countries are adjacent to developed ones; even if the latter make progress, short of a complete travel ban between neighbours, the risk of infection spread will remain.



Given the novel nature of the virus and the vaccines, there remains some uncertainty on how long vaccination protection lasts and how much asymptomatic spread can take place even after vaccination. Presently, scientists are suggesting that booster shots may be needed every 9-12 months, but if it turns out that antibodies are waning much earlier than that, that will be another setback in the public health response. Also, the cost of carrying out these vaccination-plus-booster campaigns may prove to be onerous for some developing countries. Given all these possibilities, it is difficult to see global herd immunity being reached this year, or even next.

It may well be the Covid-19 becomes endemic, and the world would have to come to terms with dealing with it like the seasonal flu. For some vulnerable people, serious illness and death may remain risks even as more people get vaccinated. Time will tell.


To read the full report, click here to Download the PDF.

Taimur Baig, Ph.D.

Chief Economist - G3 & Asia
taimurbaig@dbs.com

Chang Wei Liang

Credit & FX Strategist
weiliangchang@dbs.com


Subscribe here to receive our economics & macro strategy materials.
To unsubscribe, please click here.
The information herein is published by DBS Bank Ltd. It is based on information obtained from sources believed to be reliable, but the Group does not make any representation or warranty, express or implied, as to its accuracy, completeness, timeliness or correctness for any particular purpose. Opinions expressed are subject to change without notice. Any recommendation contained herein does not have regard to the specific investment objectives, financial situation & the particular needs of any specific addressee. The information herein is published for the information of addressees only & is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate legal or financial advice. The Group, or any of its related companies or any individuals connected with the group accepts no liability for any direct, special, indirect, consequential, incidental damages or any other loss or damages of any kind arising from any use of the information herein (including any error, omission or misstatement herein, negligent or otherwise) or further communication thereof, even if the Group or any other person has been advised of the possibility thereof. The information herein is not to be construed as an offer or a solicitation of an offer to buy or sell any securities, futures, options or other financial instruments or to provide any investment advice or services. The Group & its associates, their directors, officers and/or employees may have positions or other interests in, & may effect transactions in securities mentioned herein & may also perform or seek to perform broking, investment banking & other banking or finan­cial services for these companies. The information herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. Sources for all charts & tables are CEIC & Bloomberg unless otherwise specified.

DBS Bank Ltd., 12 Marina Blvd, Marina Bay Financial Center Tower 3, Singapore 018982. Tel: 65-6878-8888. Company Registration No. 196800306E. DBS Bank Ltd., Hong Kong SAR Branch, a company incorporated in Singapore with limited liability. 18th Floor, The Center, 99 Queen’s Road Central, Central, Hong Kong SAR.

The information set out in this website ("Information") is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction (including but not limited to citizens or residents of the United States of America) where such distribution, publication, availability or use would be contrary to law or regulation. This Information is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction (including but not limited to the United States of America) where such an offer or solicitation would be contrary to law or regulation. This Information is published for general circulation only and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person. Visitors accessing this website should always seek advice from an independent financial adviser regarding the suitability of the Information referred to herein (taking into account the specific investment objectives, financial situation and/or particular needs of each person in receipt of the Information) before making any investment and/or any purchase in reliance of the Information. Please refer to the actual research publications for important disclaimers and disclosures, where applicable.